Advertisement
XBIO
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
XBIO’s FA Score shows that 1 FA rating(s) are green while.
- XBIO’s FA Score: 1 green, 4 red.
Price Growth
XBIO (@Biotechnology) experienced а +26.98% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.68%. For the same industry, the average monthly price growth was +32.84%, and the average quarterly price growth was +6.72%.
Reported Earning Dates
XBIO is expected to report earnings on May 13, 2025.
Industries' Descriptions
@Biotechnology (+3.68% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| XBIO | |
| Capitalization | 6.05M |
| EBITDA | -3.88M |
| Gain YTD | -11.529 |
| P/E Ratio | N/A |
| Revenue | 2.58M |
| Total Cash | 5.16M |
| Total Debt | 153K |
XBIO | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 48 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| RSI ODDS (%) |
| Stochastic ODDS (%) |
| Momentum ODDS (%) |
| MACD ODDS (%) |
| TrendWeek ODDS (%) |
| TrendMonth ODDS (%) |
| Advances ODDS (%) |
| Declines ODDS (%) |
| BollingerBands ODDS (%) |
| Aroon ODDS (%) |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FEUIX | 28.61 | 0.25 | +0.88% |
| Fidelity Advisor Glbl Capital Apprec I | |||
| THORX | 42.24 | 0.29 | +0.69% |
| Thornburg Global Opportunities R3 | |||
| AXMIX | 15.16 | 0.08 | +0.53% |
| Acclivity Mid Cap Multi-Style I | |||
| JLVRX | 20.56 | 0.09 | +0.44% |
| JPMorgan Large Cap Value R5 | |||
| QLSGX | 28.11 | 0.03 | +0.11% |
| Federated Hermes MDT Small Cap Growth R6 | |||
XBIO and Stocks
Correlation & Price change
A.I.dvisor indicates that over the last year, XBIO has been loosely correlated with SYRE. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if XBIO jumps, then SYRE could also see price increases.
| Ticker / NAME | Correlation To XBIO | 1D Price Change % | ||
|---|---|---|---|---|
| XBIO | 100% | -11.53% | ||
| SYRE - XBIO | 34% Loosely correlated | -4.99% | ||
| VXRT - XBIO | 29% Poorly correlated | -8.09% | ||
| CDTX - XBIO | 28% Poorly correlated | +0.24% | ||
| ELEV - XBIO | 28% Poorly correlated | -5.90% | ||
| AUTL - XBIO | 27% Poorly correlated | N/A | ||
More | ||||